Patients ( pts ) with HER2-positive ( gene amplification or increased copy numbers based on predefined criteria ) advanced GC were randomly allocated 1:1 to receive LAP 1250mg per day 1-21 plus capecitabine ( CAP ) 2000mg/m ( 2 ) on days 1-14 of a 21-day cycle or LAP 1500mg monotherapy day 1-21 after having failed on a platinum-based first-line therapy .